California confirms first US case of more severe mpox strain — but risk to public remains low
Jun Li/Getty Images/STOCK
(SAN MATEO COUNTY, Calif.) — Health officials in California have confirmed the first domestic case of a more severe strain of mpox in a traveler from Eastern Africa, according to the U.S. Centers for Disease Control and Prevention.
The risk to the public remains low, according to the agency. Health officials are working to identify any people who may have been exposed to the person who recently traveled from Eastern Africa and was treated shortly after returning to the U.S. at a local medical facility, the CDC said.
Casual contact — including during travel — is unlikely to pose significant risks for transmission, the agency noted.
This is the first confirmed case in the U.S. of a strain, or clade, of the virus called clade 1b.
Another strain, clade 2b, was primarily responsible for the global outbreak in 2022. During the outbreak, mpox primarily spread through close sexual contact — and a strong vaccination effort was credited with helping slow the surge of cases. This less severe version continues to circulate in the U.S at low levels. The CDC does not currently recommend booster shots for those who are considered high-risk and already fully vaccinated.
Clade 1b was recently found in September in the Congo, likely responsible for a growing outbreak in Africa that led the World Health Organization to declare a global health emergency. Early data shows that this clade is more severe and may be spreading through other contact routes in households and often to children.
People with mpox, which was formerly known as monkeypox, often get a rash that can be located on hands, feet, chest, face, mouth or near the genitals, the CDC said.
(NEW YORK) — Dr. Lisa Newman, the chief of the section of breast surgery at New York-Presbyterian/Weill Cornell Medical Center, sat down with ABC News to discuss breast cancer prevention, early screenings and diagnosis discrepancies.
A new American Cancer Society report, released in October, which is Breast Cancer Awareness Month, finds that breast cancer mortality rates overall have dropped by 44% since 1989, averting about 517,900 breast cancer deaths. However, not all women have benefited from this progress.
ABC News discussed the issue with Newman, who provided more context.
ABC NEWS: Dr. Lisa Newman, chief of the section of breast surgery at New York Presbyterian/Weill Cornell Medical Center. Dr. Newman, thank you so much for joining us. So overall, are you encouraged or concerned by this report?
DR. LISA NEWMAN: Well, thank you for this attention to such a major problem of breast cancer. As you mentioned, it is rising in incidence in American women. So we are very gratified to see these continued declines in breast cancer mortality rates. This is a testimony to our successes with breast health awareness, early detection through screening mammography programs and wonderful advances that we’ve made in treatment.
But as you also noted, we are still seeing some rather appalling and disturbing trends in the breast cancer statistics. It’s very concerning to us that the rates of breast cancer are rising for young women, women younger than the age of 50. And this is for a variety of reasons. We are also seeing very concerning disparities in the burden of breast cancer and, in particular, breast cancer death rates continue to be significantly higher for African-American women and for Black women younger than the age of 50.
ABC NEWS: As far as the disparities with regard to ethnic groups, which we also discussed, why the increase there as well?
NEWMAN: Yeah. The disparities in breast cancer burden are also secondary to some complex factors with the disproportionate mortality rates that we see in Black women. We know that this is going to be explained heavily by socioeconomic disadvantages that are more prevalent in the African-American community, and African-American women are more likely to be diagnosed with more advanced breast cancers because of delays in diagnosis.
Black women are more likely to have delays in initiation of treatment, and there are some tumor biology questions that we need to evaluate in research, as well. A lot of the research that I do actually looks at the breast cancer burden of women with African ancestry. And we do know that African ancestry in and of itself increases the likelihood of getting biologically aggressive forms of breast cancer and getting breast cancer at younger ages. So we need to address that, these socioeconomic disparities, but we also need more research to understand these biological differences.
ABC NEWS: And we saw that we’re just seeing that trend of an increase year after year. What can we do to, to try and bring these numbers down?
NEWMAN: Being aware of breast health is very important and making sure that you get screened regularly. For average risk women, The American Society of Breast Surgeons advocates in favor of getting yearly mammograms starting at age 40. If you have a strong family history, you should consider getting genetic testing, because if you do have inherited predisposition for breast cancer, you may need to start getting your mammograms at even younger ages.
ABC NEWS: The good news that we see here in this report: The mortality rate has dropped in the last year compared to 35 years ago. What do you attribute that to?
NEWMAN: Yeah. Very exciting to see that the mortality rates are declining. This is secondary to women advocating more forcefully for themselves and getting screened regularly. Women also, we want to remind women that mammograms aren’t perfect. And so women do indeed need to be aware of the potential danger signs of breast cancer, such as a new lump in the breast, lump in the underarm, bloody nipple discharge, changes in the skin appearance of the breast like swelling, a rash.
ABC NEWS: And what are some basic things that all women can do to protect themselves? You mentioned diet, for example. What kinds of food or diet would be helpful with this?
NEWMAN: Well, a good way to look at it is in terms of the holistic picture and in general, the dietary patterns that are good for cardiovascular health are good for breast health. So a diet that has lots of fresh fruits and vegetables in it, minimizing fat intake, minimizing alcohol intake, alcohol has also been associated with breast cancer risk.
ABC NEWS: Such important and lifesaving information. Dr. Newman, thank you very much for coming on the show.
(NEW YORK) — The active ingredient found in popular medications for Type 2 diabetes and weight loss, including Ozempic and Wegovy, may reduce the risk of Alzheimer’s disease, a new study published Thursday finds.
Researchers from the Case Western Reserve University School of Medicine in Cleveland, Ohio, looked at three years of electronic records of almost 1 million patients with Type 2 diabetes, including those prescribed semaglutide.
Semaglutide falls under a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1s, which mimic the GLP-1 hormone that is produced in the gut after eating.
It can help produce more insulin, which reduces blood sugar and therefore helps control Type 2 diabetes. It can also interact with the brain and signal a person to feel full, which — when coupled with diet and exercise — can help reduce weight in those who are overweight or obese.
The team found that compared to seven other anti-diabetic drugs, semaglutide helped significantly lower the risk for Alzheimer’s disease, including other types of GLP-1s.
Semaglutide was associated with a 70% reduced risk when compared with insulin and 40% reduced risk when compared with other GLP-1 drugs, according to the study.
Women experienced an even lower risk for Alzheimer’s with semaglutide when compared to men, at about 80% compared to 50%, respectively.
However, women in the study were younger and more likely to have obesity or depression. They were also less likely to have heart disease, which may have led to their lower risk.
About 120,000 Americans die from Alzheimer’s disease in the U.S. each year, and it is currently the seventh-leading cause of death nationally, according to the Centers for Disease Control and Prevention.
While getting Type 2 diabetes under control may already lower the risk for Alzheimer’s disease, there may be additional dementia risk reduction for semaglutide, according to Rong Xu, lead researcher and professor of biomedical informatics at Case Western.
Semaglutide is considered to be “the most potent of the GLP-1s being that it has the greatest effect at hitting the receptor,” and, of the GLP-1s, it also produces the greatest weight loss, said Dr. Louis Aronne, the director of the Comprehensive Weight Control Center at Weill-Cornell Medical Center.
The greater potency of semaglutide may be why it has a stronger protective effect against Alzheimer’s.
Xu told ABC News that although there is no cure for Alzheimer’s disease, there are several risk factors including Type 2 diabetes and obesity that may be controlled.
“If we can address those risk factors, then we can prevent Alzheimer’s disease,” she said. “So, for semaglutide, there’s some preclinical evidence showing that this medication has neuro-protective effects and is also anti-inflammation, which can address a lot of risk factors associated with Alzheimer’s disease.”
This means GLP-1 medications may not only lower blood sugar to reduce the risk for Alzheimer’s disease, but they may also play a role in reducing neuro-inflammation.
“GLP-1 receptor agonists mitigate neuroinflammation, they mitigate oxidative stress, [and] they mitigate a number of things which occur systemically but also in the brain,” Nigel Greig, principal investigator at the National Institute on Aging, told ABC News.
However, the exact mechanism behind how GLP-1 medications reduce Alzheimer’s risk is unknown so more research is needed, according to Xu.
This is only [an] association, we cannot prove causality,” Xu said. “So, it’s not recommended to say people prescribed this medication can treat or prevent Alzheimer’s disease.”
“But this study can help people who already have Type 2 diabetes or obesity and are high risk for Alzheimer’s disease, it maybe can provide some evidence for medication selection,” she added.
For future research, Xu said she wants to examine if semaglutide can also lower the risk of other neurodegenerative diseases, including Parkinson’s disease and Lewy body dementia.
“GLP-1s provide benefit over and above weight loss alone. We are just beginning to understand the benefits of these drugs beyond weight loss alone,” said Aronne.
Itohan Omorodion, MD, MPH, is an internal medicine resident at George Washington University Hospital and a member of the ABC News Medical Unit.
After more than two years of gender-affirming treatments, LW, the Tennessee teenager behind a landmark case at the U.S. Supreme Court, says, “I feel normal now.” (ABC News)
(NASHVILLE) — The transgender Tennessee teenager behind a historic hearing at the U.S. Supreme Court this week doesn’t want to show her face on television but is eager to speak about a case she says has the potential to make thousands of American kids feel “seen” for who they are.
“The court has definitely ruled in ways that would make me think that they don’t exactly value bodily autonomy, but I have heard that they’ve been a little bit better about trans cases than people would think,” said 16-year-old LW in an exclusive interview with ABC News alongside her parents Samantha and Brian Williams.
The court on Wednesday will hear the Williams family’s challenge to Tennessee’s 2023 ban on gender-affirming medical treatments for minors, including puberty-blocking medication and hormone therapies that have dramatically improved LW’s quality of life.
While the medications have been used safely to treat minors of all genders for years, they are now prohibited in Tennessee when used to treat trans kids struggling with gender dysphoria, the distress experienced when one’s gender assigned at birth is different from one’s sense of identity.
“It’s not very comfortable being trapped in [your body] because it just doesn’t feel like you,” said LW, who reports significant improvement since beginning the treatments in 2022.
Since the state law took effect, LW now has to take time away from school to make a 10-hour round trip out of state to continue receiving care. The travel has also been a costly and time-consuming burden, her parents say.
“It would definitely be horrible for me to have to continue to go out of state to get care,” said LW. “I feel normal now.”
Backed by the American Civil Liberties Union, the Biden administration, and major American medical associations, the Williamses sued Tennessee last year alleging the ban on certain gender-affirming treatments for minors discriminates on the basis of sex and overrides the rights of parents to make medical decisions for their children.
“Our state legislature had made such a big deal out of parents’ rights during COVID, about masks and vaccines that that’s for parents to decide these medical decisions for their children,” Samantha Williams said. “And then they made this medical decision for our child.”
State lawmakers who support the law, SB1, say it is meant to protect kids from potentially irreversible effects from treatment and that contradictory scientific evidence and uncertainty about long-term adverse consequences warrant caution.
“We made the policy decision on behalf of our constituents that in Tennessee we think this is a risky procedure,” said state Sen. Jack Johnson, the Senate GOP leader who sponsored the bill. “It is our role as policymakers here in the state of Tennessee to set those guardrails.”
The American Academy of Pediatrics says the effects of puberty blockers are not permanent if treatment is discontinued and that many effects of hormone therapy can also be reversed. Long-term risks may include fertility challenges and possible harm to bone density, but the Academy says those risks require further study.
Worldwide, several countries which had previously embraced the treatments for transgender children have subsequently reversed course, citing unclear data about their purported benefits and alleged harms. In many of those places, the treatments remain available, but on a much more limited basis.
In Tennessee, there are an estimated 3,000 transgender teenagers between ages 13 and 17, according to the Williams Institute at UCLA Law School, which has analyzed Census data. It is not known how many were receiving treatments that are now outlawed or how many suffered alleged harm.
A study published in the medical journal JAMA Pediatrics in October 2024 found the overwhelming majority of participants in a long-term survey of 220 transgender youths reported high levels of satisfaction and low levels of regret in the three to five years after receiving puberty blockers and hormone therapy.
Major American medical associations have for more than a decade endorsed the use of puberty blockers and hormone therapy as part of “individually tailored interventions” to support trans kids and affirm their sense of self.
“It all begins and ends with science. This is not about any sort of agenda,” said Dr. Ben Hoffman, president of the American Academy of Pediatrics, in an interview with ABC.
Clinical practice guidelines from the American Endocrine Society — based on more than 260 research studies — recommend consideration of medications to treat gender dysphoria in young people but waiting until a child reaches adulthood to consider gender-affirming surgery.
“It’s crucial that there be a deep understanding of both the risks and benefits, and truly informed consent,” Hoffman said. “And for that reason, it is, by definition, going to take months or years.”
The Williams family said the decision to use medication to delay LW’s puberty followed months of careful consultation with medical experts and mental health providers. They said they grew worried that masculine changes to LW’s body would compound her gender dysphoria.
“There is this time clock sitting here,” said Brian Williams. “The kids can go through puberty and it can have permanent effects on them. So these two things you’re trying to balance at the same time.”
“She’s not suicidal, but she shouldn’t have to be suicidal, right?, to get the care that she needs,” added Samantha Williams. “When that really hit me, I was like, ‘OK, let’s do blockers. Let’s get moving.'”
More than a year later, LW began receiving hormone therapy to better align her body with her gender identity. The course of treatment led to a reduction in discomfort.
“That was incredibly helpful,” LW said. “I feel amazing after that. You know, maybe it’s just because the gender dysphoria was so bad.”
The outcome of the case U.S. v. Skrmetti could have a sweeping impact on health care for the more than 300,000 American teens who identify as transgender, as well as the broader LGBTQ community.
“This is one of the most significant LGBTQ cases to ever reach the Supreme Court. I think this is an inflection point,” said Chase Strangio, the ACLU attorney representing the Williams family. He will be the first openly transgender person to argue a case before the nation’s highest court.
“Is this going to be a Bowers v. Hardwick type moment that sets off years of government legitimized discrimination against LGBTQ people? Or, is this going to be a Bostock moment that clarifies what we all have been assuming all this time, which is that LGBTQ people are protected under the Constitution and civil rights laws,” Strangio said.
In its 1968 decision in Bowers, the court upheld state laws criminalizing private same-sex conduct; it was overturned in 2003. The Court’s 2020 decision in Bostock v. Clayton County found that employment discrimination on the basis of sexual orientation and gender identity is illegal.
Twenty-six states have laws banning gender-affirming treatments for minors, according to the Human Rights Campaign, an LGBTQ advocacy group.
“What concerns me as a physician is that legislators are going to be able to make decisions about a diagnosis, which is very unusual. I mean, that really hasn’t happened,” said Dr. Susan Lacy, a physician who specializes in hormone management and transgender care for teens and adults at her private practice in Memphis.
Lacy, who is also a party to the Supreme Court case, agrees with Tennessee lawmakers that more research is needed on gender-affirming treatments for minors, but that a debate over the data shouldn’t deny patients the chance to make an informed decision of their own.
“I think the most compelling thing is to listen to the patients,” Lacy said. “I have about 700 transgender patients out of about 3,000 total patients, and I have not seen anybody have a serious complication — not one.”
“I think we’re just at a point where we’re still in the process of treating people and having studies that will give us more and more data to support this treatment,” she said.
Johnson said he hopes the Supreme Court will uphold an appeals court ruling that affirmed Tennessee’s right to impose restrictions on treatments for transgender minors.
“States should be the laboratories of democracy,” he said. “We should be making the vast majority of decisions about what’s best for our people, our constituents here in the statehouse.”
The Williams family says care that has improved the life of their daughter should not be up for political debate.
“I want to listen to the doctors. I want to listen to my kid. I want to take care of her, you know?” Brian Williams said.
